

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

A protocol of rhythmic auditory stimulation for improving upper-limb movements in patients with Parkinson's disease

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2023-072416
Article Type:	Protocol
Date Submitted by the Author:	02-Feb-2023
Complete List of Authors:	FAN, Wei; The Hong Kong Polytechnic University, Department of Rehabilitation Sciences Fong, Kenneth N. K.; The Hong Kong Polytechnic University, Department of Rehabilitation Sciences Wang, Shu-Mei; The Hong Kong Polytechnic University, Department of Rehabilitation Sciences
Keywords:	REHABILITATION MEDICINE, Parkinson-s disease < NEUROLOGY, Clinical trials < THERAPEUTICS

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

A protocol of rhythmic auditory stimulation for improving upper-limb movements in patients with Parkinson's disease

Wei Fan¹, Kenneth N. K. Fong¹, Shu-Mei Wang¹

¹ Department of Rehabilitation Sciences, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong

Correspondence to: Dr. Shu-Mei Wang; shumei.wang@polyu.edu.hk

For peer review only

ABSTRACT

Introduction Bradykinesia (i.e., slow movements) is one of the most prominent symptoms of Parkinson's disease (PD) and has a negative impact on quality of life. Rhythmic auditory stimulation (RAS), a widely used and promising treatment technique, has been shown to effectively improve gait speed in PD patients. However, only few studies have explored effects of training involving RAS on upper-limb movements. The purpose of this study is to investigate effects of movement training involving RAS on upper-limb movement speed and function in PD patients.

Methods and analysis Patients with PD will be randomly assigned into two groups: the RAS group and the no-RAS group. A 21-day upper-limb training involving RAS (for the RAS group) or without RAS (for the no-RAS group) will be provided to the patients. An assessor will administer the box and block test (BBT) and the Jebsen hand function test (JHFT) before and after training to assess upper-limb movement speed and function. The independent sample t-test will be performed to compare the BBT and JHFT scores between groups to determine the effects of RAS. This randomized controlled trial will provide evidence supporting the effectiveness of upper-limb movement training involving RAS in reducing the severity of bradykinesia in PD patients.

Ethics and dissemination Ethical approval has been obtained from the Institutional Review Board of the Hong Kong Polytechnic University with the reference number HSEARS20221027005. Informed consent forms will be gathered from all patients before their participation. Study results will be disseminated through conferences and peer-reviewed academic journals.

Trial registration number ClinicalTrials.gov NCT05637593

Keywords Acoustic stimulation, Parkinson's disease, Arm, Movement, Bradykinesia

ARTICLE SUMMARY

Strengths and limitations of this study

- This is a randomised controlled trial that provides robust evidence supporting effectiveness of upper-limb movement training involving RAS in PD patients.
- Results of this study form a base of evidence-based therapy in clinical practice for tackling bradykinesia in PD patients.
- Effects of home-based training are susceptible to patient compliance, which has been considered and addressed through daily phone calls and completion of a daily training log.

INTRODUCTION

Parkinson's disease (PD) is a common neurodegenerative disease caused by neurodegeneration of the substantia nigra, resulting in a decrease in dopamine [1, 2]. The incidence of PD is 14 per 100,000 people per year, and even reaches 160 per 100,000 people over the age of 65 years [3]. Dopamine, a neurotransmitter, is important for the function of the basal ganglia in receiving, modulating, and transmitting signals to various cortical areas, including those associated with movements [4]. Therefore, in PD patients, a decrease in dopamine leads to basal ganglia dysfunction in the cortico-striato-thalamo-cortical circuit, resulting in movement symptoms [5, 6]. Bradykinesia, meaning slowness of movements, is one of the most prominent symptoms of PD [7], extensively interferes with performances of daily activities such as eating, writing, and walking [8], and substantially lowers quality of life in patients [9, 10].

Pharmacotherapy has been shown to alleviate movement symptoms in PD patients. Medications, such as levodopa, are able to adjust activities of the putamen and thalamus, modulate signals from basal ganglia to motor-related cortices, and thus enhance movements in patients [11]. However, long-term use of medications increases medication resistance and thus reduces therapeutic effects, as well as increases side effects of medications such as dyskinesia [12, 13]. Therefore, developing non-pharmacological therapies is warranted and of clinical importance in order to tackle bradykinesia in patients with PD.

Rhythmic auditory stimulation (RAS) is repetitive, discrete sounds with a tempo [14, 15]. Because the tempo of human movements is naturally synchronized with the tempo of RAS [16, 17], RAS has a high potential of being applied to movement training to guide human movement execution [18]. Earlier studies [19] have provided solid evidence that training involving RAS is effective in improving gait performance in PD patients. Earlier classic research [20] examining effects of training involving RAS on gaits in PD patients provided 21-day training with 30 minutes

1
2
3 per day, in which RAS with three different tempi (normal RAS, quick RAS, and fast RAS) was
4 provided. Initially, researchers assessed the baseline walking tempo without the aid of RAS for
5 each patient. For daily training, each patient was given normal RAS (100% of the baseline
6 tempo), quick RAS (105% of the baseline tempo), and fast RAS (110% of the baseline tempo) to
7 guide the gaits. Each RAS was increased by 5% when the time went to next week.
8
9
10
11
12

13 Most previous studies that investigated RAS effects in PD patients focused on lower-limb
14 movements such as gaits [19]. However, upper-limb movements are also important for activities
15 of daily living and directly affect quality of life in humans [21]. In addition, it is commonly seen
16 that rehabilitation training for upper-limb movements involves continuous movement repetition,
17 which supports that RAS may be applicable to upper-limb movement therapy. It is worth
18 investigating if upper-limb training involving RAS is effective for PD patients. To date, only few
19 studies [22, 23] have investigated effects of RAS on upper-limb movements in PD patients. A
20 case report [22] indicated that movement training involving RAS may improve finger tapping
21 speed and finger dexterity in PD patients. In addition, a study using the repeated measures
22 design [23] demonstrated that faster RAS immediately induced faster upper-limb movement
23 speed in PD patients. To date, randomized controlled trials have been needed to determine
24 whether long-term training involving RAS is effective in improving upper-limb movement speed
25 and function in PD patients.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40

41 It has been suggested that training involving RAS establishes an internal sense of rhythms
42 in humans because humans keep anticipating subsequent beats of RAS [15]. The established
43 sense of rhythms persists in humans and keeps affecting movement execution even after RAS
44 disappears [15, 24]. In addition, powerful influences of RAS on movements may also be
45 associated with plentiful neural connections between auditory and motor cortices, including the
46 cortico-striato-cortical pathway, the cortico-cerebello-cortical pathway, and auditory-motor neural
47 connections directly in the cortex [25]. Earlier research [26–29] has reported that RAS not only
48 activates neurons in the auditory cortex, but also induces neural firing in motor-related cortical
49
50
51
52
53
54
55
56
57

1
2
3 regions (such as primary motor cortex, premotor and supplementary motor areas) even though
4 examinees are stationary without moving. In PD patients, RAS improves movements possibly by
5 involving the cortico-cerebello-cortical pathway and auditory-motor cortical connections to
6 modulate neural activity of the motor cortex and bypassing the damaged cortico-striato-cortical
7 pathway [25, 30]. Additionally, RAS serves as external cues, can provide timing (tempo)
8 information for PD patients, and thus possibly reduces the dependence of patients' movements
9 on impaired modulation function of basal ganglia.
10
11
12
13
14
15
16

17
18 To sum up, the purpose of this study is to investigate effects of movement training involving
19 RAS on upper-limb movement speed and function in PD patients. We hypothesize that
20 movement training involving RAS improves upper-limb movement speed and function in PD
21 patients. Validation of this hypothesis will fill up the knowledge gap regarding whether RAS is
22 applicable to upper-limb training in the PD population and provide clinicians with evidence of
23 non-pharmacological therapy for upper-limb bradykinesia in PD patients. The training program
24 will serve as a reference for clinical practitioners who are interested in using RAS in clinical
25 training for PD patients.
26
27
28
29
30
31
32
33
34

35 **METHODS AND ANALYSIS**

36
37
38
39 This study follows the SPIRIT (Standard Protocol Items Recommendations for Interventional
40 Trials) guidelines for reporting [31].
41
42
43

44 *Study design*

45
46
47 A randomized controlled trial will be used to validate the hypothesis. Patients with PD will be
48 randomly assigned to two groups by using computer-generated random numbers: the RAS
49 group and the no-RAS group. Each sealed envelope with an assigned group will be used. The
50 RAS group will receive upper-limb movement training with the aid of RAS; the no-RAS group will
51 receive upper-limb movement training without the aid of RAS. This study will provide 21-day
52
53
54
55
56
57

1
2
3 training with a session per day and 40 minutes per session. Assessments will be completed
4 face-to-face before and after the 21-day training by a senior therapist. For all participants,
5 training and assessments will be performed during the 'on' state of their anti-Parkinson
6 medication. Daily phone calls and weekly face-to-face meetings with patients will be performed
7 to increase patient retention. We will monitor muscle fatigue during home training by using a
8 daily training log in which self-reported reflections will be recorded.
9
10
11
12
13
14

15 16 *Patient and public involvement*

17
18 Patients were involved in the design and dissemination of this research. We carefully
19 designed the training duration and content to prevent fatigue in patients according to literature
20 and our pilot study [23]. In addition, we will share key findings of this study with participants at
21 the end of the study.
22
23
24
25
26
27
28

29 *Participants*

30
31 Patients with PD will be recruited from hospitals. Age, gender and years of education will be
32 recorded. Criteria for selecting patients are as follows: (a) idiopathic PD diagnosed by a
33 neurologist based on the Movement Disorders Society clinical diagnostic criteria [32]; (b) the
34 Hoehn and Yahr stage is 2 or 3, meaning that bilateral movement problems or combination with
35 mild postural instability [33]; (c) a score of Montreal Cognitive Assessment is equal to or higher
36 than 21 to ensure that they understand experimental instructions [34–36]; (d) a score of
37 Edinburgh Handedness Inventory is above 60 to ensure that they are right-handed [37]; (e)
38 Types and doses of medications remain unchanged in the past month right before participation.
39 Exclusion criteria include the presence of medical conditions or diseases that may affect hand
40 movements, vision, or hearing based on self-report. Patients will sign an informed consent form
41 prior to admission to this study.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Sample size estimation

Because of no existing PD studies testing effects of training involving RAS on upper-limb movements, we calculated the effect size of training involving RAS ($d = 0.51$) according to data of the classic study [20] examining effects of training involving RAS on gait speed in PD patients. The G*Power software (version 3.1.9.7) was used. When the effect size d was 0.51, the power was 0.8, and the α level (two-tailed) was 0.05, the estimated required sample size was 62 for each group. Considering the dropout rate of 10%, the final sample size was 69 patients per group, for a total of 138 patients.

Intervention

Patients with PD will be randomly assigned into two groups (the RAS group and the no-RAS group). Three-week training will be provided for both groups. The training protocol is mainly based on the classic study [20] examining effects of RAS on gait speed in PD patients and a recent study [38] examining effects of RAS on upper-limb movements in the population exhibiting movement slowness. We increase frequency of breaks during training per day because our pilot study [23] observed that patients with PD had muscle fatigue easily when following RAS to execute upper-limb movements without frequent breaks. The training task of this study will be to use the right hand to move wooden beads one by one from one target bowl to the main bowl on the table (Figure 1A). Three target bowls, labeled as the left, middle, and right target bowl, will be placed on the table at an equal distance from the main bowl. The distance between a target bowl and the main bowl will be set at 30 cm, which is 50% of the upper-limb length (from the shoulder to the middle finger tip) of Hong Kong women [39], to ensure that beads in the target bowls are reachable for research participants. The angle between adjacent target bowls relative to the main bowl will be 30 degrees. Wooden beads with a diameter of 2 cm will be put in target bowls. The main bowl will be placed in front of the patient.

1
2
3 Patients will be asked to use the right hand to take one bead at a time from the left target bowl to
4 the main bowl, repeat this movement for the middle and right target bowls, and keep repeating
5 this order (Figure 1B).
6
7
8

9 Each daily training will consist of three rounds separated by two 5-minute breaks. Each
10 round (about 10 minutes) will consist of four 2-minute training sessions with a 30-second break
11 between two adjacent sessions. On the first day after the pretest, patients will receive the first
12 training session face-to-face in a hospital. After the first training session, patients will carry all
13 training materials back home for subsequent 6-day home training sessions. Family members or
14 caregivers will be only permitted to assist in setting up the training environment and not allowed
15 to assist the patient during training. On the first day of each subsequent training week, patients
16 will be asked to return to the hospital to receive a face-to-face training session. Research
17 personnel will make phone calls every day to remind patients to complete daily training. In
18 addition, patients will be required to complete a daily training log to ensure compliance.
19
20
21
22
23
24
25
26
27
28
29

30 Before the first-day training, the baseline tempo of executing the training task will be
31 assessed for each patient. The patient will be required to perform the aforementioned upper-limb
32 movement task as fast as possible within 30 seconds without listening to RAS. The obtained
33 number of wooden beads in the main bowl multiplied by two will be the baseline tempo (unit:
34 beat per minute) for each patient [15, 20].
35
36
37
38
39
40

41 For the RAS group, each patient will receive a 45-minute audio file, which includes briefing
42 the patient about the daily training content (five minutes) and providing RAS (10 minutes per
43 round multiplied by three rounds, plus two 5-minute break time; a total of 40 minutes). The
44 normal RAS (100% of the baseline tempo), the quick RAS (105% of the baseline tempo), and
45 the fast RAS (110% of the baseline tempo) will be provided in the first, second, and third round
46 of training (Table 1). The patient will be asked to pick up a bead when s/he hears a beep sound
47 of RAS. The tempo of the three RAS will be further increased by 5% of the baseline tempo when
48 it goes to a new week. In the face-to-face session (the first day) of each week, the patient will
49
50
51
52
53
54
55
56
57

obtain a new audio file and complete daily training face-to-face in hospital. RAS will be metronome beep sounds generated by a metronome (SQ200, Seiko incorporated). The required tempo of RAS will be adjusted using the computer software Adobe Audition CC 2020. The audio file will be sent to the patient's mobile phone, which will then be used to play the audio file during both face-to-face and home training.

Table 1. RAS tempi that are provided in daily upper-limb training

Day	Normal RAS in round 1	Quick RAS in round 2	Fast RAS in round 3
1 st – 7 th	100% of the baseline tempo	105% of the baseline tempo	110% of the baseline tempo
8 th – 14 th	105% of the baseline tempo	110% of the baseline tempo	115% of the baseline tempo
15 th – 21 st	110% of the baseline tempo	115% of the baseline tempo	120% of the baseline tempo

RAS, rhythmic auditory stimulation.

The no-RAS group will receive a 45-minute audio file, which briefs the patient about the daily training content (five minutes) and instructs the patient to move beads as fast as possible in each round without RAS. The training protocol is the same in the RAS group and the no-RAS group except no RAS is provided for the no-RAS group during training. Similarly, the no-RAS group will perform the training face-to-face on the first day of each week in the hospital and at home on the remaining six days of a week.

Outcome measures

The box and block test (BBT) is used to measure gross manual dexterity as well as upper-limb movement speed [40]. It is a 53.7* 25.4 cm box separated into two compartments by a 15.2 cm high erected partition, with 150 blocks in each compartment. Starting from the dominant hand, patients will be asked to move the blocks one by one from the compartment on the hand side to the opposite side (e.g., move the blocks from the right compartment to the left compartment for the right hand test). Patients should move the blocks with their arms raised and crossed over the partition. They have one minute to move the blocks as fast as possible. The score of BBT for each hand is the quantity of blocks transferred between compartments in one minute. A higher score indicates faster upper-limb movements and better dexterity. For the elderly, the BBT has high test-retest reliability (intraclass correlation coefficient of 0.89 to 0.97) and construct validity [41].

The Jebsen hand function test (JHFT) is used to assess unimanual hand function when examinees perform daily activities. Seven items are included in JHFT: writing, turning cards, picking up small objects, simulated feeding, stacking checkers, moving large light objects, and moving large heavy objects [42]. Considering that the patients are Chinese speakers, it is not appropriate to do English writing. According to a previous study conducted in Chinese cultures [43], the JHFT could be modified through excluding the writing item to avoid cultural influences on scores. The score for each item is the completion time. The less time a patient takes, the better hand function s/he has. The JHFT has excellent test-retest reliability (intraclass correlation coefficients of 0.89 to 0.97) for PD patients [44].

Safety

To assess the data safety, scientific validity, and integrity of clinical trials, a data monitoring committee will be formed by two senior researchers who are not involved in the group allocation

1
2
3 and protocol implications. After the study is completed, the research data will be retained in
4 demographic and scoring sheets will be retained for five years and destroyed afterwards. In this
5 study, adverse events, defined as any unfavorable medical occurrence in a patient, will be
6 collected and reported to data monitoring committee for records. This study will provide
7 movement training. If participants have muscle fatigue during training, research personnel will
8 provide break time immediately.
9
10
11
12
13
14
15

16 *Data collection and statistical analysis*

17
18
19
20 The general information and results will be kept on a portable hard drive. Authors of this
21 study will conduct interim analysis to re-estimate the required sample size and determine if the
22 study should continue or be modified. Only authors of this study will be allowed to get access to
23 the dataset.
24
25
26
27

28 To test the baseline difference, the independent sample t-test (for continuous variables) and
29 the chi-square test (for categorical variables) will be used to examine if age, gender, years of
30 education, Montreal Cognitive Assessment scores, Hoehn and Yahr stages, and pretest scores
31 of BBT and JHFT are the same between the RAS group and the no-RAS group. The
32 independent sample t-test will be performed to compare the difference in posttest scores of BBT
33 and JHFT between groups. The alpha level (two-tailed) will be set at 0.05. It is hypothesized that
34 (a) posttest scores of BBT are higher in the RAS group than the no-RAS group, and (b) posttest
35 scores of JHFT are higher in the RAS group than the no-RAS group. Patients may drop out
36 before the study is completed. The last data point of the patient will be used to handle the
37 missing data. The SPSS package (the 25th version) will be used to conduct statistical analysis.
38
39
40
41
42
43
44
45
46
47
48
49

50 **DISCUSSION**

51
52
53 RAS, a common technique of neuromusic therapy, has been used extensively to improve
54 gait, stride length, and balance in PD patients [19]. Earlier research has provided explanations of
55
56
57

1
2
3 mechanisms of RAS effects in the PD population [25]. Major explanations are that RAS may
4 activate alternative and intact neural pathways or may provide timing information from the beat
5 of RAS so as to improve movement control and alleviate bradykinesia in PD patients [25].
6
7 Bradykinesia is also present in upper limbs, in addition to lower limbs, in PD patients and affects
8 daily activities and quality of life in patients [9, 10]. Even though RAS is a promising training
9 technique for bradykinesia, how to apply RAS to upper-limb movement training for PD patients is
10 still unclear. To our best knowledge, scarce training protocols targeting upper-limb movement
11 training involving RAS for the PD population have been available in research. This study
12 presented a pioneering training protocol, which could be used in future randomized controlled
13 trials to validate effects of training involving RAS on improving upper-limb movements in PD
14 patients. The training program shown in this study will serve as a reference for researchers and
15 clinicians who are interested in developing intervention for tackling upper-limb bradykinesia in
16 PD patients.
17
18
19
20
21
22
23
24
25
26
27
28
29

30 It is fundamental for training involving RAS to determine a baseline tempo of executing an
31 upper-limb or lower-limb movement (without the aid of RAS), which is used to calculate the
32 speed of normal, quick, and fast RAS in the training. In previous studies regarding walking in PD
33 patients, the baseline tempo was the tempo when the participant walked at a general and
34 comfortable pace, not at the fastest pace [20, 45]. In other words, the baseline tempo of walking
35 in earlier research was a performance patients chose to make, not the best performance
36 patients could make. Therefore, the speed of quick and fast RAS provided in training in earlier
37 research may not be faster than the baseline best walking ability/speed when patients had not
38 received training involving RAS. By contrast, the current study protocol was designed to detect a
39 baseline tempo at participants' fastest pace and thus able to provide participants with quick and
40 fast RAS with speed faster than their baseline best movement abilities. This design may
41 contribute to optimizing effects of RAS incorporated in movement training.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Our previous empirical study has reported immediate effects of RAS on inducing faster
4 upper-limb movements in PD patients [23]. However, we observed that although RAS with
5 speed of 110% and 120% of baseline tempos was effective, patients had muscle fatigue easily
6 to follow the beat of RAS on a movement task. Considering this study protocol provided daily
7 movement training lasting for 40 minutes, it adopted quick and fast RAS with speed of 105% and
8 110% of baseline tempos as well as increased the frequency of break during training to reduce
9 muscle fatigue in patients.
10
11
12
13
14
15
16
17

18 To sum up, this study protocol will support healthcare providers in academia and clinical
19 settings to provide promising non-pharmacological therapy, that is, training involving RAS, for
20 tackling upper-limb bradykinesia in PD patients.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Contributors

Wei Fan: Study conception and design. Execution. Writing of the first draft.

Kenneth N. K. Fong: Review and critique.

Shu-Mei Wang: Study conception and design. Review and critique.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Competing interests:

None declared.

Ethics and dissemination:

Ethical approval has been obtained from the Institutional Review Board of the Hong Kong Polytechnic University with the reference number HSEARS20221027005. It has been registered on ClinicalTrials.gov under the identifier NCT05637593.

Patients who are eligible will be well-informed about the objectives and timeline of this study. Informed consent forms will be gathered from all patients before their participation. The general health condition of patients will be monitored via daily phone calls and weekly face-to-face meetings. Training will be suspended or terminated when there are adverse events. Study results will be disseminated through conferences and peer-reviewed academic journals. Identifiable information of patients will not be disclosed during result dissemination.

REFERENCES

- 1 Jastrzębowska MA, Marquis R, Melie-García L, et al. Dopaminergic modulation of motor network compensatory mechanisms in Parkinson's disease. *Hum Brain Map* 2019;40(15):4397–416.
- 2 Gale JT, Amirnovin R, Williams ZM, et al. From symphony to cacophony: pathophysiology of the human basal ganglia in Parkinson disease. *Neurosci Biobehav Rev* 2008;32(3):378–87.
- 3 Ascherio A, Schwarzschild MA. The epidemiology of Parkinson's disease: risk factors and prevention. *The Lancet Neurology* 2016;15(12):1257–72.
- 4 Haber SN, Adler A, Bergman H. The Basal Ganglia. In: *The Human Nervous System*: Elsevier 2012:678–738.
- 5 Sian J, Gerlach M, Youdim MB, et al. Parkinson's disease: a major hypokinetic basal ganglia disorder. *J Neural Transm (Vienna)* 1999;106(5-6):443–76.
- 6 Redgrave P, Rodriguez M, Smith Y, et al. Goal-directed and habitual control in the basal ganglia: implications for Parkinson's disease. *Nat Rev Neurosci* 2010;11(11):760–72.
- 7 Radhakrishnan DM, Goyal V. Parkinson's disease: A review. *Neurol India* 2018;66(Supplement):S26-S35.
- 8 Simões R, Litvan I. Bradykinesia. In: *Encyclopedia of Movement Disorders*: Elsevier 2010:158–61.
- 9 Muslimovic D, Post B, Speelman JD, et al. Determinants of disability and quality of life in mild to moderate Parkinson disease. *Neurology* 2008;70(23):2241–47.
- 10 Rajiah K, Maharajan MK, Yeen SJ, et al. Quality of life and caregivers' burden of Parkinson's disease. *Neuroepidemiology* 2017;48(3-4):131–37.
- 11 Kraft E, Loichinger W, Diepers M, et al. Levodopa-induced striatal activation in Parkinson's disease: a functional MRI study. *Parkinsonism Relat Disord* 2009;15(8):558–63.

- 12 Nonnekes J, Timmer MHM, Vries NM de, et al. Unmasking levodopa resistance in Parkinson's disease. *Mov Disord* 2016;31(11):1602–09.
- 13 Vorovenci RJ, Biundo R, Antonini A. Therapy-resistant symptoms in Parkinson's disease. *J Neural Transm (Vienna)* 2016;123(1):19–30.
- 14 Ni M, Hazzard JB, Signorile JF, et al. Exercise guidelines for gait function in Parkinson's disease: a systematic review and meta-analysis. *Neurorehabil Neural Repair* 2018;32(10):872–86.
- 15 Nombela C, Hughes LE, Owen AM, et al. Into the groove: can rhythm influence Parkinson's disease? *Neurosci Biobehav Rev* 2013;37(10 Pt 2):2564–70.
- 16 Thaut MH, Abiru M. Rhythmic auditory stimulation in rehabilitation of movement disorders: a review of current research. *Music Perception* 2010;27(4):263–69.
- 17 Schaffert N, Janzen TB, Mattes K, et al. A review on the relationship between sound and movement in sports and rehabilitation. *Front Psychol* 2019;10(244):244.
- 18 Thaut MH, McIntosh GC, Hoemberg V. Neurobiological foundations of neurologic music therapy: rhythmic entrainment and the motor system. *Front Psychol* 2014;5:1185.
- 19 Ghai S, Ghai I, Schmitz G, et al. Effect of rhythmic auditory cueing on parkinsonian gait: A systematic review and meta-analysis. *Sci Rep* 2018;8(1):506.
- 20 Thaut MH, McIntosh GC, Rice RR, et al. Rhythmic auditory stimulation in gait training for Parkinson's disease patients. *Mov Disord* 1996;11(2):193–200.
- 21 Cahn DA, Sullivan EV, Shear PK, et al. Differential contributions of cognitive and motor component processes to physical and instrumental activities of daily living in Parkinson's disease. *Arch Clin Neuropsychol* 1998;13(7):575–83.
- 22 Buard I, Dewispelaere WB, Thaut M, et al. Preliminary neurophysiological evidence of altered cortical activity and connectivity with neurologic music therapy in Parkinson's disease. *Front Neurosci* 2019;13:105.

- 1
2
3 23 Fan W, Li J, Wei W, et al. Effects of rhythmic auditory stimulation on upper-limb movements
4 in patients with Parkinson's disease. *Parkinsonism Relat Disord* 2022;101:27–30.
5
6
7 24 Palmer C, Krumhansl CL. Mental representations for musical meter. *Journal of*
8
9 *Experimental Psychology: Human Perception and Performance* 1990;16(4):728–41.
10
11 25 Leuk JSP, Low LLN, Teo W-P. An overview of acoustic-based interventions to improve
12 motor symptoms in Parkinson's disease. *Front Aging Neurosci* 2020;12:243.
13
14
15 26 Chen JL, Penhune VB, Zatorre RJ. Listening to musical rhythms recruits motor regions of
16 the brain. *Cereb Cortex* 2008;18(12):2844–54.
17
18
19 27 Bengtsson SL, Ullén F, Ehrsson HH, et al. Listening to rhythms activates motor and
20 premotor cortices. *Cortex* 2009;45(1):62–71.
21
22
23 28 Koshimori Y, Thaut MH. Future perspectives on neural mechanisms underlying rhythm and
24 music based neurorehabilitation in Parkinson's disease. *Ageing Res Rev* 2018;47:133–39.
25
26
27 29 Grahn JA, Rowe JB. Feeling the beat: premotor and striatal interactions in musicians and
28 nonmusicians during beat perception. *J Neurosci* 2009;29(23):7540–48.
29
30
31 30 Braunlich K, Seger CA, Jentink KG, et al. Rhythmic auditory cues shape neural network
32 recruitment in Parkinson's disease during repetitive motor behavior. *Eur J Neurosci*
33 2019;49(6):849–58.
34
35
36 31 Chan A-W, Tetzlaff JM, Gøtzsche PC, et al. SPIRIT 2013 explanation and elaboration:
37 guidance for protocols of clinical trials. *BMJ* 2013;346:e7586.
38
39
40 32 Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's
41 disease. *Mov Disord* 2015;30(12):1591–601.
42
43
44 33 Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision of
45 the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and
46 clinimetric testing results. *Mov Disord* 2008;23(15):2129–70.
47
48
49 34 Dalrymple-Alford JC, MacAskill MR, Nakas CT, et al. The MoCA: well-suited screen for
50 cognitive impairment in Parkinson disease. *Neurology* 2010;75(19):1717–25.
51
52
53
54
55
56
57
58
59
60

- 1
2
3 35 Wang YP, Xu GL, Yang SQ, Liu XM, Deng XY. Value of Montreal Cognitive Assessment in
4 identifying patients with mild vascular cognitive impairment after first stroke. *Chinese*
5 *Journal of Neuromedicine* 2010;9(5):503–07.
6
7
8
9 36 Vitorio R, Stuart S, Gobbi LTB, et al. Reduced gait variability and enhanced brain activity in
10 older adults with auditory cues: a functional near-infrared spectroscopy study. *Neurorehabil*
11 *Neural Repair* 2018;32(11):976–87.
12
13
14
15 37 Yang N, Waddington G, Adams R, et al. Translation, cultural adaptation, and test-retest
16 reliability of Chinese versions of the Edinburgh Handedness Inventory and Waterloo
17 Footedness Questionnaire. *Laterality* 2018;23(3):255–73.
18
19
20
21 38 Wang S-M, Chan S-T, Wong Y-L, et al. Rhythmic auditory stimulation incorporated in
22 training improved movements in individuals with psychotic-like experiences. *Eur Arch*
23 *Psychiatry Clin Neurosci* 2022.
24
25
26
27 39 Alan H.S. Chan. Upper limb length n.d. Available at:
28 <http://personal.cityu.edu.hk/meachan/Online%20Anthropometry/Chapter2/Ch2-24.htm>
29
30
31
32 Accessed August 21, 2022.
33
34
35 40 Mathiowetz V, Volland G, Kashman N, et al. Adult norms for the Box and Block Test of
36 manual dexterity. *Am J Occup Ther* 1985;39(6):386–91.
37
38
39 41 Desrosiers J, Bravo G, Hébert R, et al. Validation of the Box and Block Test as a measure
40 of dexterity of elderly people: reliability, validity, and norms studies. *Arch Phys Med Rehabil*
41 1994;75(7):751–55.
42
43
44
45 42 Jebsen RH, Taylor N, Trieschmann RB, et al. An objective and standardized test of hand
46 function. *Arch Phys Med Rehabil* 1969;50(6):311–19.
47
48
49 43 Dong VA, Fong KNK, Chen Y-F, et al. 'Remind-to-move' treatment versus constraint-
50 induced movement therapy for children with hemiplegic cerebral palsy: a randomized
51 controlled trial. *Dev Med Child Neurol* 2017;59(2):160–67.
52
53
54
55
56
57
58
59
60

- 1
2
3 44 Mak MKY, Lau ETL, Tam VWK, et al. Use of Jebsen Taylor Hand Function Test in
4
5 evaluating the hand dexterity in people with Parkinson's disease. *J Hand Ther*
6
7 2015;28(4):389-94; quiz 395.
8
9 45 Calabrò RS, Naro A, Filoni S, et al. Walking to your right music: a randomized controlled
10
11 trial on the novel use of treadmill plus music in Parkinson's disease. *J Neuroeng Rehabil*
12
13 2019;16(1):68.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3 **Figure captions**
4

5 **Figure 1.** (A) The setup of the upper-limb training task. (B) The patient picks up one bead from
6
7 one target bowl and is going to move the bead to the main bowl.
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only




Figure 1

530x940mm (216 x 216 DPI)

Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin J, Dickersin K, Hróbjartsson A, Schulz KF, Parulekar WR, Krleža-Jerić K, Laupacis A, Moher D. SPIRIT 2013 Explanation and Elaboration: Guidance for protocols of clinical trials. *BMJ*. 2013;346:e7586

		Reporting Item	Page Number
Administrative information			
Title	#1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	#2a	Trial identifier and registry name. If not yet registered, name of intended registry	2
Trial registration: data set	#2b	All items from the World Health Organization Trial Registration Data Set	2
Protocol version	#3	Date and version identifier	n/a
Funding	#4	Sources and types of financial, material, and other support	15
Roles and responsibilities: contributorship	#5a	Names, affiliations, and roles of protocol contributors	15

1	Roles and	#5b	Name and contact information for the trial sponsor	1
2	responsibilities:			
3	sponsor contact			
4	information			
5				
6				
7				
8	Roles and	#5c	Role of study sponsor and funders, if any, in study design;	15
9	responsibilities:		collection, management, analysis, and interpretation of data;	
10	sponsor and funder		writing of the report; and the decision to submit the report for	
11			publication, including whether they will have ultimate authority	
12			over any of these activities	
13				
14				
15				
16	Roles and	#5d	Composition, roles, and responsibilities of the coordinating centre,	11-12
17	responsibilities:		steering committee, endpoint adjudication committee, data	
18	committees		management team, and other individuals or groups overseeing the	
19			trial, if applicable (see Item 21a for data monitoring committee)	
20				
21				
22				
23	Introduction			
24				
25	Background and	#6a	Description of research question and justification for undertaking	4-6
26	rationale		the trial, including summary of relevant studies (published and	
27			unpublished) examining benefits and harms for each intervention	
28				
29				
30	Background and	#6b	Explanation for choice of comparators	4-6
31	rationale: choice of			
32	comparators			
33				
34				
35				
36	Objectives	#7	Specific objectives or hypotheses	6
37				
38	Trial design	#8	Description of trial design including type of trial (eg, parallel	6-7
39			group, crossover, factorial, single group), allocation ratio, and	
40			framework (eg, superiority, equivalence, non-inferiority,	
41			exploratory)	
42				
43				
44				
45	Methods:			
46	Participants,			
47	interventions, and			
48	outcomes			
49				
50				
51				
52	Study setting	#9	Description of study settings (eg, community clinic, academic	6-7
53			hospital) and list of countries where data will be collected.	
54			Reference to where list of study sites can be obtained	
55				
56				
57	Eligibility criteria	#10	Inclusion and exclusion criteria for participants. If applicable,	7
58			eligibility criteria for study centres and individuals who will	
59				
60				

perform the interventions (eg, surgeons, psychotherapists)

1			
2			
3	Interventions:	#11a	Interventions for each group with sufficient detail to allow
4	description		replication, including how and when they will be administered
5			
6	Interventions:	#11b	Criteria for discontinuing or modifying allocated interventions for a
7	modifications		given trial participant (eg, drug dose change in response to harms,
8			participant request, or improving / worsening disease)
9			
10			
11	Interventions:	#11c	Strategies to improve adherence to intervention protocols, and any
12	adherence		procedures for monitoring adherence (eg, drug tablet return;
13			laboratory tests)
14			
15			
16			
17	Interventions:	#11d	Relevant concomitant care and interventions that are permitted or
18	concomitant care		prohibited during the trial
19			
20			
21	Outcomes	#12	Primary, secondary, and other outcomes, including the specific
22			measurement variable (eg, systolic blood pressure), analysis metric
23			(eg, change from baseline, final value, time to event), method of
24			aggregation (eg, median, proportion), and time point for each
25			outcome. Explanation of the clinical relevance of chosen efficacy
26			and harm outcomes is strongly recommended
27			
28			
29			
30			
31	Participant timeline	#13	Time schedule of enrolment, interventions (including any run-ins
32			and washouts), assessments, and visits for participants. A
33			schematic diagram is highly recommended (see Figure)
34			
35			
36	Sample size	#14	Estimated number of participants needed to achieve study
37			objectives and how it was determined, including clinical and
38			statistical assumptions supporting any sample size calculations
39			
40			
41	Recruitment	#15	Strategies for achieving adequate participant enrolment to reach
42			target sample size
43			
44			
45	Methods: Assignment		
46	of interventions (for		
47	controlled trials)		
48			
49			
50	Allocation: sequence	#16a	Method of generating the allocation sequence (eg, computer-
51	generation		generated random numbers), and list of any factors for
52			stratification. To reduce predictability of a random sequence,
53			details of any planned restriction (eg, blocking) should be provided
54			in a separate document that is unavailable to those who enrol
55			participants or assign interventions
56			
57			
58			
59			
60			

1	Allocation concealment	#16b	Mechanism of implementing the allocation sequence (eg, central	6
2	mechanism		telephone; sequentially numbered, opaque, sealed envelopes),	
3			describing any steps to conceal the sequence until interventions are	
4			assigned	
5				
6				
7				
8	Allocation:	#16c	Who will generate the allocation sequence, who will enrol	6
9	implementation		participants, and who will assign participants to interventions	
10				
11	Blinding (masking)	#17a	Who will be blinded after assignment to interventions (eg, trial	n/a
12			participants, care providers, outcome assessors, data analysts), and	
13			how	
14				
15				
16				
17	Blinding (masking):	#17b	If blinded, circumstances under which unblinding is permissible,	n/a
18	emergency unblinding		and procedure for revealing a participant's allocated intervention	
19			during the trial	
20				
21				
22	Methods: Data			
23	collection,			
24	management, and			
25	analysis			
26				
27				
28				
29	Data collection plan	#18a	Plans for assessment and collection of outcome, baseline, and other	10
30			trial data, including any related processes to promote data quality	
31			(eg, duplicate measurements, training of assessors) and a	
32			description of study instruments (eg, questionnaires, laboratory	
33			tests) along with their reliability and validity, if known. Reference	
34			to where data collection forms can be found, if not in the protocol	
35				
36				
37				
38				
39	Data collection plan:	#18b	Plans to promote participant retention and complete follow-up,	7
40	retention		including list of any outcome data to be collected for participants	
41			who discontinue or deviate from intervention protocols	
42				
43				
44	Data management	#19	Plans for data entry, coding, security, and storage, including any	11-12
45			related processes to promote data quality (eg, double data entry;	
46			range checks for data values). Reference to where details of data	
47			management procedures can be found, if not in the protocol	
48				
49				
50				
51	Statistics: outcomes	#20a	Statistical methods for analysing primary and secondary outcomes.	12
52			Reference to where other details of the statistical analysis plan can	
53			be found, if not in the protocol	
54				
55				
56	Statistics: additional	#20b	Methods for any additional analyses (eg, subgroup and adjusted	12
57	analyses		analyses)	
58				
59				
60				

1	Statistics: analysis	#20c	Definition of analysis population relating to protocol non-	12
2	population and missing		adherence (eg, as randomised analysis), and any statistical methods	
3	data		to handle missing data (eg, multiple imputation)	
4				
5				
6	Methods: Monitoring			
7				
8				
9	Data monitoring:	#21a	Composition of data monitoring committee (DMC); summary of its	11-12
10	formal committee		role and reporting structure; statement of whether it is independent	
11			from the sponsor and competing interests; and reference to where	
12			further details about its charter can be found, if not in the protocol.	
13			Alternatively, an explanation of why a DMC is not needed	
14				
15				
16				
17	Data monitoring:	#21b	Description of any interim analyses and stopping guidelines,	11-12
18	interim analysis		including who will have access to these interim results and make	
19			the final decision to terminate the trial	
20				
21				
22	Harms	#22	Plans for collecting, assessing, reporting, and managing solicited	11-12
23			and spontaneously reported adverse events and other unintended	
24			effects of trial interventions or trial conduct	
25				
26				
27				
28	Auditing	#23	Frequency and procedures for auditing trial conduct, if any, and	n/a
29			whether the process will be independent from investigators and the	
30			sponsor	
31				
32				
33	Ethics and			
34	dissemination			
35				
36				
37	Research ethics	#24	Plans for seeking research ethics committee / institutional review	15
38	approval		board (REC / IRB) approval	
39				
40				
41	Protocol amendments	#25	Plans for communicating important protocol modifications (eg,	15
42			changes to eligibility criteria, outcomes, analyses) to relevant	
43			parties (eg, investigators, REC / IRBs, trial participants, trial	
44			registries, journals, regulators)	
45				
46				
47	Consent or assent	#26a	Who will obtain informed consent or assent from potential trial	15
48			participants or authorised surrogates, and how (see Item 32)	
49				
50				
51	Consent or assent:	#26b	Additional consent provisions for collection and use of participant	n/a
52	ancillary studies		data and biological specimens in ancillary studies, if applicable	
53				
54				
55	Confidentiality	#27	How personal information about potential and enrolled participants	15
56			will be collected, shared, and maintained in order to protect	
57			confidentiality before, during, and after the trial	
58				
59				
60				

1	Declaration of interests	#28	Financial and other competing interests for principal investigators for the overall trial and each study site	15
2				
3				
4	Data access	#29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	12
5				
6				
7				
8				
9				
10	Ancillary and post trial care	#30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	n/a
11				
12				
13				
14	Dissemination policy: trial results	#31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	15
15				
16				
17				
18				
19				
20				
21	Dissemination policy: authorship	#31b	Authorship eligibility guidelines and any intended use of professional writers	15
22				
23				
24	Dissemination policy: reproducible research	#31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	n/a
25				
26				
27				
28	Appendices			
29				
30				
31	Informed consent materials	#32	Model consent form and other related documentation given to participants and authorised surrogates	n/a
32				
33				
34	Biological specimens	#33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	n/a
35				
36				
37				
38				
39				

40 The SPIRIT Explanation and Elaboration paper is distributed under the terms of the Creative Commons
 41 Attribution License CC-BY-NC. This checklist was completed on 01. February 2023 using
 42 <https://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)
 43

BMJ Open

Effects of training involving patterned sensory enhancement on improving upper-limb movements in patients with Parkinson's disease: protocol of a randomised controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2023-072416.R1
Article Type:	Protocol
Date Submitted by the Author:	15-Jun-2023
Complete List of Authors:	FAN, Wei; The Hong Kong Polytechnic University, Department of Rehabilitation Sciences Fong, Kenneth N. K.; The Hong Kong Polytechnic University, Department of Rehabilitation Sciences Wang, Shu-Mei; The Hong Kong Polytechnic University, Department of Rehabilitation Sciences
Primary Subject Heading:	Rehabilitation medicine
Secondary Subject Heading:	Sports and exercise medicine
Keywords:	REHABILITATION MEDICINE, Parkinson-s disease < NEUROLOGY, Clinical trials < THERAPEUTICS

SCHOLARONE™
Manuscripts

1
2
3 **Effects of training involving patterned sensory enhancement on improving upper-limb**
4
5 **movements in patients with Parkinson's disease: protocol of a randomised controlled trial**
6

7 Wei Fan¹, Kenneth N. K. Fong¹, Shu-Mei Wang¹
8
9

10
11
12 *¹ Department of Rehabilitation Sciences, The Hong Kong Polytechnic University, Hung Hom,*
13
14 *Kowloon, Hong Kong*
15

16
17
18
19 Correspondence to: Dr. Shu-Mei Wang; shumei.wang@polyu.edu.hk
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Introduction Bradykinesia (i.e., slow movements) is one of the most prominent symptoms of Parkinson's disease (PD) and has a negative impact on quality of life. Rhythmic auditory stimulation (RAS), a widely used and promising treatment technique, has been shown to effectively improve gait speed in PD patients. The upper-limb movements, which also suffer from bradykinesia, are essential for daily life and directly impact quality of life. The term, patterned sensory enhancement (PSE) instead of RAS, is used when movement training targets the human body except lower limbs. Up until now, scarce studies have explored effects of training involving PSE on upper-limb movements. The purpose of this study is to investigate effects of movement training involving PSE on upper-limb movement speed and function in PD patients.

Methods and analysis A total of 138 patients with PD will be randomly assigned into two groups: the PSE group and the no-PSE group. A 21-day upper-limb training involving PSE (for the PSE group) or without PSE (for the no-PSE group) will be provided to the patients. An assessor will administer the box and block test and the Jebsen hand function test before and after training to assess upper-limb movement speed and function. The one-way analysis of covariance will be performed. This randomised controlled trial will provide evidence supporting effectiveness of upper-limb movement training involving PSE on reducing severity of bradykinesia in PD patients.

Ethics and dissemination Ethical approval has been obtained from the Institutional Review Board of the Hong Kong Polytechnic University with the reference number HSEARS20221027005. Informed consent forms will be gathered from all patients before their participation. Study results will be disseminated through conferences and peer-reviewed academic journals.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Trial registration number ClinicalTrials.gov NCT05637593

Keywords Acoustic stimulation, Parkinson’s disease, Arm, Movement, Bradykinesia

For peer review only

Strengths and limitations of this study

- This is a randomised controlled trial with one experimental group with PD receiving 21-day upper-limb movement training with the aid of PSE and one control group with PD receiving the same training without the aid of PSE.
- PSE is three tempi of metronome beat that are based on the participant's fastest upper-limb movement speed before the training and gradually increase by each week.
- Movement speed and quality are assessed using the box and block test and the Jebsen hand function test.
- One possible concern of this training combining face-to-face sessions and home training sessions is whether participants will adhere to the home training protocol, which will be addressed via real-time video meetings during all home training sessions.

INTRODUCTION

Parkinson's disease (PD) is a common neurodegenerative disease caused by neurodegeneration of the substantia nigra, resulting in a decrease in dopamine [1, 2]. The incidence of PD is 14 per 100,000 people per year, and even reaches 160 per 100,000 people over the age of 65 years [3]. Dopamine, a neurotransmitter, is important for the function of the basal ganglia in receiving, modulating, and transmitting signals to various cortical areas, including those associated with movements [4]. Therefore, in PD patients, a decrease in dopamine leads to basal ganglia dysfunction in the cortico-striato-thalamo-cortical circuit, resulting in movement symptoms [5, 6]. Bradykinesia, meaning slowness of movements, is one of the most prominent symptoms of PD [7], extensively interferes with performances of daily activities such as eating, writing, and walking [8], and substantially lowers the quality of life in patients [9, 10].

Pharmacotherapy has been shown to alleviate movement symptoms in PD patients. Medications, such as levodopa, are able to adjust activities of the putamen and thalamus, modulate signals from basal ganglia to motor-related cortices, and thus enhance movements in patients [11]. However, long-term use of medications increases medication resistance and thus reduces therapeutic effects, as well as increases side effects of medications such as dyskinesia [12, 13]. Therefore, developing non-pharmacological therapies is warranted and of clinical importance in order to tackle bradykinesia in patients with PD.

Rhythmic auditory stimulation (RAS) is repetitive, discrete sounds with a tempo [14, 15]. Because the tempo of human movements is naturally synchronized with the tempo of RAS [16, 17], RAS has a high potential of being applied to movement training to guide human movement execution [18]. Earlier studies [19] have provided solid evidence that training involving RAS is effective in improving gait performance in PD patients. Earlier classic research [20] examining effects of training involving RAS on gaits in PD patients provided 21-day training with 30

1
2
3 minutes per day, in which RAS with three different tempi (normal RAS, quick RAS, and fast
4 RAS) was provided. Initially, researchers assessed the baseline walking tempo without the aid of
5 RAS for each patient. For daily training, each patient was given normal RAS (100% of the
6 baseline tempo), quick RAS (105% of the baseline tempo), and fast RAS (110% of the baseline
7 tempo) to guide the gaits. Each RAS was increased by 5% when the time went to the next week.
8
9

10
11
12
13
14
15 The term, patterned sensory enhancement (PSE) instead of RAS, is used when movement
16 training targets the human body except lower limbs [21]. Most previous studies that investigated
17 RAS effects in PD patients focused on lower-limb movements such as gaits [19]. However,
18 upper-limb movements are also important for activities of daily living and directly affect quality
19 of life in humans [22]. In addition, it is commonly seen that rehabilitation training for upper-limb
20 movements involves continuous movement repetition, which supports that PSE may be
21 applicable to upper-limb movement therapy. It is worth investigating if upper-limb training
22 involving PSE is effective for PD patients. To date, only few studies [23, 24] have investigated
23 effects of PSE on upper-limb movements in PD patients. A case report [23] indicated that
24 movement training involving PSE may improve finger-tapping speed and finger dexterity in PD
25 patients. In addition, a study using the repeated measures design [24] demonstrated that faster
26 PSE immediately induced faster upper-limb movement speed in PD patients. To date, randomised
27 controlled trials have been needed to determine whether long-term training involving PSE is
28 effective in improving upper-limb movement speed and function in PD patients.
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45

46
47 It has been suggested that training involving RAS/PSE establishes an internal sense of
48 rhythm in humans because humans keep anticipating subsequent beats of RAS/PSE [15]. The
49 established sense of rhythms persists in humans and keeps affecting movement execution even
50 after RAS/PSE disappears [15, 25]. In addition, powerful influences of RAS/PSE on movements
51 may also be associated with plentiful neural connections between auditory and motor cortices,
52
53
54
55
56
57
58
59
60

1
2
3 including the cortico-striato-cortical pathway, the cortico-cerebello-cortical pathway, and
4
5 auditory-motor neural connections directly in the cortex [26]. Earlier research [27–30] has
6
7 reported that RAS/PSE not only activates neurons in the auditory cortex, but also induces neural
8
9 firing in motor-related cortical regions (such as primary motor cortex, premotor, and
10
11 supplementary motor areas) even though examinees are stationary without moving. In PD
12
13 patients, RAS/PSE improves movements possibly by involving the cortico-cerebello-cortical
14
15 pathway and auditory-motor cortical connections to modulate neural activity of the motor cortex
16
17 and bypassing the damaged cortico-striato-cortical pathway [26, 31]. Additionally, RAS/PSE
18
19 serves as external cues, can provide timing (tempo) information for PD patients, and thus
20
21 possibly reduces the dependence of patients' movements on impaired modulation function of
22
23 basal ganglia [15].
24
25
26
27

28 To sum up, the purpose of this study is to investigate effects of movement training involving
29
30 PSE on upper-limb movement speed and function in PD patients. We hypothesize that movement
31
32 training involving PSE improves upper-limb movement speed and function in PD patients.
33
34 Validation of this hypothesis will fill up the knowledge gap regarding whether PSE is applicable
35
36 to upper-limb training in the PD population and provide clinicians with evidence of non-
37
38 pharmacological therapy for upper-limb bradykinesia in PD patients. The training program will
39
40 serve as a reference for clinical practitioners who are interested in using RAS/PSE in clinical
41
42 training for PD patients.
43
44
45

46 **METHODS AND ANALYSIS**

47
48
49 This study follows the SPIRIT (Standard Protocol Items Recommendations for
50
51 Interventional Trials) guidelines for reporting [32].
52
53
54
55
56
57
58
59
60

Study design

A randomised controlled trial will be used to validate the hypothesis. Patients with PD will be randomly assigned to two groups by using computer-generated random numbers: the PSE group and the no-PSE group. Each sealed envelope with an assigned group will be used. The PSE group will receive upper-limb movement training with the aid of PSE; the no-PSE group will receive upper-limb movement training without the aid of PSE. This study will provide 21-day training with a session per day and 40 minutes per session. Assessments will be completed face-to-face before and after the 21-day training by a senior therapist who is blinded to the group allocation. Blinding of patients and people who provide training is not feasible in this study because patients and training providers know group allocation. For all participants, training and assessments will be performed during the 'on' state of their anti-Parkinson medication. We will conduct weekly face-to-face meetings with patients and real-time video meetings during all home training sessions to ensure the adherence of participants to the training program. We will monitor muscle fatigue during home training by using a daily training log. The study is expected to commence in August of 2023 and is anticipated to be completed within two years.

Patient and public involvement

Patients were involved in the design and dissemination of this research. We carefully designed the training duration and content to prevent fatigue in patients according to literature and our pilot study [24]. In addition, we will share key findings of this study with participants at the end of the study.

Participants

Patients with PD will be recruited from hospitals through posters and physician referrals. At pretest, this study will collect demographic and clinical data, including age, gender, disease duration, the more-affected side, and medication dosage. The more-affected side (left or right)

1
2
3 refers to the side of the body exhibiting more severe bradykinesia, which will be determined
4
5 visually by an experienced physician. In addition, we will calculate the levodopa equivalent dose
6
7 [33] to measure medication dosage. Criteria for selecting patients are as follows: (a) idiopathic
8
9 PD diagnosed by a neurologist based on the Movement Disorders Society clinical diagnostic
10
11 criteria [34]; (b) the Hoehn and Yahr stage is 2 or 3, meaning that bilateral movement problems
12
13 or combination with mild postural instability [35]; (c) a score of Montreal Cognitive Assessment
14
15 is equal to or higher than 21 to ensure that they understand experimental instructions [36–38]; (d)
16
17 a score of Edinburgh Handedness Inventory is above 60 to ensure that they are right-handed [39];
18
19 (e) Types and doses of medications remain unchanged in the past month right before
20
21 participation. Exclusion criteria include the presence of medical conditions or diseases that may
22
23 affect hand movements, vision, or hearing based on self-report. Patients will sign an informed
24
25 consent form prior to admission to this study.
26
27
28
29

30 *Sample size estimation*

31
32
33 Because of no existing PD studies testing effects of training involving PSE on upper-limb
34
35 movements, we calculated the effect size of training involving PSE ($f = 0.255$) according to data
36
37 of the classic study [20] examining effects of training involving RAS on gait speed in PD
38
39 patients. The G*Power software (version 3.1.9.7) was used to estimate the required sample size
40
41 under the following conditions: analysis of covariance as the statistical test, an effect size f of
42
43 0.255, the power of 0.8, the alpha level of 0.05, two groups, and 10 covariates (age, gender, the
44
45 Hoehn and Yahr stage, disease duration, the more-affected side, medication dosage, the number
46
47 of training sessions the participant completes, the score of the depression item in the first part of
48
49 the Movement Disorder Society-sponsored revision of the unified Parkinson's disease rating scale
50
51 (MDS-UPDRS) at pretest, the score of the anxiety item in the first part of MDS-UPDRS at
52
53 pretest, and a pretest score of an outcome variable, including the score of the box and block test
54
55
56
57
58
59
60

1
2
3 (BBT), the error rate during executing BBT, the score of the Jebsen hand function test (JHFT),
4
5 and the domain score of the third part of MDS-UPDRS). The estimated total sample size was
6
7 124. Considering the dropout rate of 10%, the final total sample size was 138 patients (69
8
9 patients per group).

10 11 12 *Intervention*

13
14 Patients with PD will be randomly assigned into two groups (the PSE group and the no-PSE
15
16 group). Three-week training will be provided for both groups. The training protocol is mainly
17
18 based on the classic study [20] examining effects of RAS on gait speed in PD patients and a
19
20 recent study [40] examining effects of PSE on upper-limb movements in the population
21
22 exhibiting movement slowness. We increase the frequency of breaks during training per day
23
24 because our pilot study [24] observed that patients with PD had muscle fatigue easily when
25
26 following PSE to execute upper-limb movements without frequent breaks. The training task of
27
28 this study will be to use the right hand to move wooden beads one by one from one target bowl to
29
30 the main bowl on the table (Figure 1A). Three target bowls, labelled as the left, middle, and right
31
32 target bowl, will be placed on the table at an equal distance from the main bowl. The distance
33
34 between a target bowl and the main bowl will be set at 30 cm, which is 50% of the upper-limb
35
36 length (from the shoulder to the middle finger tip) of Hong Kong women [41], to ensure that
37
38 beads in the target bowls are reachable for research participants. The angles between adjacent
39
40 target bowls relative to the main bowl will be 30 degrees. Wooden beads with a diameter of 2 cm
41
42 will be put in target bowls. The main bowl will be placed in front of the patient. Patients will be
43
44 asked to use the right hand to take one bead at a time from the left target bowl to the main bowl,
45
46 repeat this movement for the middle and right target bowls, and keep repeating this order (Figure
47
48
49
50
51
52
53
54 1B).

1
2
3 The training sessions will be conducted during the "ON" period of medication. Specifically,
4 the participant will be required to conduct daily training after 1 hour of taking medications. Each
5 daily training will consist of three rounds separated by two 5-minute breaks. Each round (about
6 10 minutes) will consist of four 2-minute training sessions with a 30-second break between two
7 adjacent sessions. On the first day after the pretest, patients will receive the first training session
8 face-to-face in a hospital. After the first training session, patients will carry all training materials
9 back home for subsequent 6-day home training sessions. Family members or caregivers will be
10 only permitted to assist in setting up the training environment and not be allowed to assist the
11 patient during training. On the first day of each subsequent training week, patients will be asked
12 to return to the hospital to receive a face-to-face training session. We will conduct real-time video
13 meetings during all home training sessions to ensure adherence to the treatment plan. We will
14 also ask participants to complete daily training logs to record training completion and monitor the
15 degrees of fatigue. In addition, we will calculate the number of training sessions the participant
16 completes.

17
18 Before the first-day training, the baseline tempo of executing the training task will be
19 assessed for each patient. The patient will be required to perform the aforementioned upper-limb
20 movement task as fast as possible within 30 seconds for three times without listening to PSE. The
21 obtained average number of wooden beads in the main bowl multiplied by two will be the
22 baseline tempo (unit: beat per minute) for each patient [15, 20].

23
24 For the PSE group, each patient will receive a 45-minute audio file, which includes briefing
25 the patient about the daily training content (five minutes) and providing PSE (10 minutes per
26 round multiplied by three rounds, plus two 5-minute break times; a total of 40 minutes). The
27 normal PSE (100% of the baseline tempo), the quick PSE (105% of the baseline tempo), and the
28 fast PSE (110% of the baseline tempo) will be provided in the first, second, and third round of

training (Table 1). The patient will be asked to pick up a bead when s/he hears a beep sound of PSE. The tempo of the three PSE will be further increased by 5% of the baseline tempo when it goes to a new week. In the face-to-face session (the first day) of each week, the patient will obtain a new audio file and complete daily training face-to-face in the hospital. PSE will be metronome beep sounds generated by a metronome (SQ200, Seiko incorporated). The required tempo of PSE will be adjusted using the computer software Adobe Audition CC 2020. The audio file will be sent to the patient's mobile phone, which will then be used to play the audio file during both face-to-face and home training.

Table 1. PSE tempi that are provided in daily upper-limb training

Day	1 st round: Normal PSE	2 nd round: Quick PSE	3 rd round: Fast PSE
1 st – 7 th	100% of the baseline tempo	105% of the baseline tempo	110% of the baseline tempo
8 th – 14 th	105% of the baseline tempo	110% of the baseline tempo	115% of the baseline tempo
15 th – 21 st	110% of the baseline tempo	115% of the baseline tempo	120% of the baseline tempo

PSE, patterned sensory enhancement.

The no-PSE group will receive a 45-minute audio file, which briefs the patient about the daily training content (five minutes) and instructs the patient to move beads as fast as possible in each round without PSE. The training protocol is the same in the PSE group and the no-PSE group, except no PSE is provided for the no-PSE group during training. Similarly, the no-PSE group will perform the training face-to-face on the first day of each week in the hospital and at home on the remaining six days of a week.

1
2
3 Our previous empirical study has reported immediate effects of PSE on inducing faster
4 upper-limb movements in PD patients [24]. However, we observed that although PSE with the
5 speed of 110% and 120% of the baseline tempo was effective, patients had muscle fatigue easily
6 when following the beat of PSE on an upper-limb movement task. This study protocol provides
7 daily 40-minute upper-limb movement training at the fastest speed for 40 minutes, which is very
8 intensive and easily causes muscle fatigue. To reduce muscle fatigue in patients, we will adopt
9 PSE with the tempo speed starting from 100%, 105%, and 110% of the baseline tempo in the
10 first-week training instead of 100%, 110%, and 120%, and will increase the frequency of training
11 breaks.
12
13
14
15
16
17
18
19
20
21
22
23

24 *Outcome measures*

25
26 The MDS-UPDRS is a commonly used tool in clinical settings and research to assess
27 influences of PD on multiple aspects in patients [35]. It consists of four parts, including (the first
28 part) non-motor subjective experiences of daily living, (the second part) motor-related subjective
29 experiences of daily living, (the third part) the motor examination, and (the fourth part) motor
30 complications [35]. We will calculate the domain score of the third part of MDS-UPDRS, which
31 is used to reflect objective severity of movement symptoms in patients. Larger scores indicate
32 more severe movement symptoms. We will also use the score of the depression item and that of
33 the anxiety item separately in the first part of MDS-UPDRS to detect levels of depression and
34 anxiety in patients.
35
36
37
38
39
40
41
42
43
44
45

46
47 The BBT is used to measure gross manual dexterity as well as upper-limb movement speed
48 [42]. It is a 53.7* 25.4 cm box separated into two compartments by a 15.2 cm high erected
49 partition, with 150 blocks in each compartment. Starting from the dominant hand, patients will be
50 asked to move the blocks one by one from the compartment on the hand side to the opposite side
51 (e.g., move the blocks from the right compartment to the left compartment for the right hand
52
53
54
55
56
57
58
59
60

1
2
3 test). Patients should move the blocks with their arms raised and crossed over the partition. They
4
5 have one minute to move the blocks as fast as possible. The score of BBT for each hand is the
6
7 number of blocks that are successfully transferred between compartments in one minute. A
8
9 higher BBT score indicates faster upper-limb movements and better dexterity. In addition, the
10
11 number of dropping blocks during the blocks moving tasks of BBT in each hand will be recorded
12
13 as the error score. We will calculate the error rate of executing BBT in each hand by dividing the
14
15 error score by the sum of the error score and the BBT score to assess the accuracy of upper-limb
16
17 movements. The higher error rate indicates less accurate upper-limb movements. For the elderly,
18
19 the BBT has high test-retest reliability (intraclass correlation coefficient of 0.89 to 0.97) and
20
21 construct validity [43].
22
23
24
25

26 The JHFT is used to assess unimanual hand function when examinees perform daily
27
28 activities. Seven items are included in JHFT: writing, turning cards, picking up small objects,
29
30 simulated feeding, stacking checkers, moving large light objects, and moving large heavy objects
31
32 [44]. Considering that the patients are Chinese speakers, it is not appropriate to do English
33
34 writing. According to a previous study conducted in Chinese cultures [45], the JHFT could be
35
36 modified by excluding the writing item to avoid cultural influences on scores. The score for each
37
38 item is the completion time. The less time a patient takes, the better hand function s/he has. We
39
40 will calculate the total score of these six items as one dependent variable. The JHFT has excellent
41
42 test-retest reliability (intraclass correlation coefficients of 0.89 to 0.97) for PD patients [46].
43
44
45
46

47 *Safety*

48
49 To assess the data safety, scientific validity, and integrity of clinical trials, a data monitoring
50
51 committee will be formed by two senior researchers who are not involved in the group allocation
52
53 and protocol implications. After the study is completed, the research data will be retained for five
54
55 years and destroyed afterwards. In this study, adverse events, defined as any unfavorable medical
56
57
58
59
60

1
2
3 occurrence in a patient, will be collected and reported to data monitoring committee for records.

4
5 This study will provide movement training. If participants have muscle fatigue during training,
6
7 research personnel will provide break time immediately.
8

9
10 *Data collection and statistical analysis*

11
12 The general information and results will be kept on a portable hard drive. Authors of this
13
14 study will conduct an interim analysis to re-estimate the required sample size and determine if the
15
16 study should continue or be modified. Only authors of this study will be allowed to get access to
17
18 the dataset.
19

20
21 A one-way analysis of covariance will be conducted to examine effects of group (the PSE
22
23 group versus the no-PSE group) on each dependent variable, including BBT scores, the error rate
24
25 during executing BBT, JHFT scores, and the domain score of the third part of MDS-UPDRS at
26
27 posttest. The 10 potential confounding factors are age, gender, the Hoehn and Yahr stage, disease
28
29 duration, the more-affected side, medication dosage, the number of training sessions the
30
31 participant completes, the score of the depression item in the first part of MDS-UPDRS at pretest,
32
33 the score of the anxiety item in the first part of MDS-UPDRS at pretest, and a pretest score of an
34
35 outcome variable (including BBT scores, the error rate during executing BBT, JHFT scores, and
36
37 the domain score of the third part of MDS-UPDRS). The alpha level (two-tailed) will be set at
38
39 0.05. It is hypothesized that after controlling for confounding influences, PSE increases scores of
40
41 BBT, and decreases JHFT scores, the domain score of the third part of MDS-UPDRS, and the
42
43 error rate of BBT. Patients may drop out before the study is completed. The last data point of the
44
45 patient will be used to handle the missing data. The SPSS package (the 25th version) will be used
46
47 to conduct statistical analysis.
48
49
50
51
52
53
54
55
56
57
58
59
60

Contributors

Wei Fan: Study conception and design. Execution. Writing of the first draft.

Kenneth N. K. Fong: Review and critique.

Shu-Mei Wang: Study conception and design. Review and critique.

Data Availability Statement:

The data supporting the findings of this study will be available upon reasonable request to the corresponding author.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Competing interests:

None declared.

Ethics and dissemination:

Ethical approval has been obtained from the Institutional Review Board of the Hong Kong Polytechnic University with the reference number HSEARS20221027005. It has been registered on ClinicalTrials.gov under the identifier NCT05637593. Patients who are eligible will be well-informed about the objectives and timeline of this study. Informed consent forms will be gathered from all patients before their participation. The general health condition of patients will be monitored via daily video meetings and weekly face-to-face meetings. Training will be suspended or terminated when there are adverse events. Study results will be disseminated through conferences and peer-reviewed academic journals. Identifiable information of patients will not be disclosed during result dissemination.

REFERENCES

- 1 Jastrzębowska MA, Marquis R, Melie-García L, et al. Dopaminergic modulation of motor network compensatory mechanisms in Parkinson's disease. *Hum Brain Map* 2019;40(15):4397–416.
- 2 Gale JT, Amirnovin R, Williams ZM, et al. From symphony to cacophony: pathophysiology of the human basal ganglia in Parkinson disease. *Neurosci Biobehav Rev* 2008;32(3):378–87.
- 3 Ascherio A, Schwarzschild MA. The epidemiology of Parkinson's disease: risk factors and prevention. *The Lancet Neurology* 2016;15(12):1257–72.
- 4 Haber SN, Adler A, Bergman H. The Basal Ganglia. In: *The Human Nervous System*: Elsevier 2012:678–738.
- 5 Sian J, Gerlach M, Youdim MB, et al. Parkinson's disease: a major hypokinetic basal ganglia disorder. *J Neural Transm (Vienna)* 1999;106(5-6):443–76.
- 6 Redgrave P, Rodriguez M, Smith Y, et al. Goal-directed and habitual control in the basal ganglia: implications for Parkinson's disease. *Nat Rev Neurosci* 2010;11(11):760–72.
- 7 Radhakrishnan DM, Goyal V. Parkinson's disease: A review. *Neurol India* 2018;66(Supplement):S26-S35.
- 8 Simões R, Litvan I. Bradykinesia. In: *Encyclopedia of Movement Disorders*: Elsevier 2010:158–61.
- 9 Muslimovic D, Post B, Speelman JD, et al. Determinants of disability and quality of life in mild to moderate Parkinson disease. *Neurology* 2008;70(23):2241–47.
- 10 Rajiah K, Maharajan MK, Yeen SJ, et al. Quality of life and caregivers' burden of Parkinson's disease. *Neuroepidemiology* 2017;48(3-4):131–37.

- 1
2
3 11 Kraft E, Loichinger W, Diepers M, et al. Levodopa-induced striatal activation in Parkinson's
4 disease: a functional MRI study. *Parkinsonism Relat Disord* 2009;15(8):558–63.
5
6
7
8 12 Nonnekes J, Timmer MHM, Vries NM de, et al. Unmasking levodopa resistance in
9 Parkinson's disease. *Mov Disord* 2016;31(11):1602–09.
10
11
12 13 Vorovenci RJ, Biundo R, Antonini A. Therapy-resistant symptoms in Parkinson's disease. *J*
13 *Neural Transm (Vienna)* 2016;123(1):19–30.
14
15
16
17 14 Ni M, Hazzard JB, Signorile JF, et al. Exercise guidelines for gait function in Parkinson's
18 disease: a systematic review and meta-analysis. *Neurorehabil Neural Repair*
19 2018;32(10):872–86.
20
21
22
23
24 15 Nombela C, Hughes LE, Owen AM, et al. Into the groove: can rhythm influence Parkinson's
25 disease? *Neurosci Biobehav Rev* 2013;37(10 Pt 2):2564–70.
26
27
28
29 16 Thaut MH, Abiru M. Rhythmic auditory stimulation in rehabilitation of movement
30 disorders: a review of current research. *Music Perception* 2010;27(4):263–69.
31
32
33 17 Schaffert N, Janzen TB, Mattes K, et al. A review on the relationship between sound and
34 movement in sports and rehabilitation. *Front Psychol* 2019;10(244):244.
35
36
37
38 18 Thaut MH, McIntosh GC, Hoemberg V. Neurobiological foundations of neurologic music
39 therapy: rhythmic entrainment and the motor system. *Front Psychol* 2014;5:1185.
40
41
42 19 Ghai S, Ghai I, Schmitz G, et al. Effect of rhythmic auditory cueing on parkinsonian gait: A
43 systematic review and meta-analysis. *Sci Rep* 2018;8(1):506.
44
45
46
47 20 Thaut MH, McIntosh GC, Rice RR, et al. Rhythmic auditory stimulation in gait training for
48 Parkinson's disease patients. *Mov Disord* 1996;11(2):193–200.
49
50
51 21 Thaut M, Hoemberg V. Handbook of neurologic music therapy: Oxford University Press,
52 USA 2014.
53
54
55
56
57
58
59
60

- 1
2
3 22 Cahn DA, Sullivan EV, Shear PK, et al. Differential contributions of cognitive and motor
4 component processes to physical and instrumental activities of daily living in Parkinson's
5 disease. *Arch Clin Neuropsychol* 1998;13(7):575–83.
6
7
8
9
10 23 Buard I, Dewispelaere WB, Thaut M, et al. Preliminary neurophysiological evidence of
11 altered cortical activity and connectivity with neurologic music therapy in Parkinson's
12 disease. *Front Neurosci* 2019;13:105.
13
14
15
16
17 24 Fan W, Li J, Wei W, et al. Effects of rhythmic auditory stimulation on upper-limb
18 movements in patients with Parkinson's disease. *Parkinsonism Relat Disord* 2022;101:27–
19 30.
20
21
22
23
24 25 Palmer C, Krumhansl CL. Mental representations for musical meter. *Journal of*
25 *Experimental Psychology: Human Perception and Performance* 1990;16(4):728–41.
26
27
28 26 Leuk JSP, Low LLN, Teo W-P. An overview of acoustic-based interventions to improve
29 motor symptoms in Parkinson's disease. *Front Aging Neurosci* 2020;12:243.
30
31
32
33 27 Chen JL, Penhune VB, Zatorre RJ. Listening to musical rhythms recruits motor regions of
34 the brain. *Cereb Cortex* 2008;18(12):2844–54.
35
36
37
38 28 Bengtsson SL, Ullén F, Ehrsson HH, et al. Listening to rhythms activates motor and
39 premotor cortices. *Cortex* 2009;45(1):62–71.
40
41
42 29 Koshimori Y, Thaut MH. Future perspectives on neural mechanisms underlying rhythm and
43 music based neurorehabilitation in Parkinson's disease. *Ageing Res Rev* 2018;47:133–39.
44
45
46
47 30 Grahn JA, Rowe JB. Feeling the beat: premotor and striatal interactions in musicians and
48 nonmusicians during beat perception. *J Neurosci* 2009;29(23):7540–48.
49
50
51 31 Braunlich K, Seger CA, Jentink KG, et al. Rhythmic auditory cues shape neural network
52 recruitment in Parkinson's disease during repetitive motor behavior. *Eur J Neurosci*
53 2019;49(6):849–58.
54
55
56
57
58
59
60

- 1
2
3 32 Chan A-W, Tetzlaff JM, Gøtzsche PC, et al. SPIRIT 2013 explanation and elaboration:
4 guidance for protocols of clinical trials. *BMJ* 2013;346:e7586.
5
6
7 33 Nyholm D, Jost WH. An updated calculator for determining levodopa-equivalent dose.
8 *Neurol Res Pract* 2021;3(1):58.
9
10
11 34 Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's
12 disease. *Mov Disord* 2015;30(12):1591–601.
13
14
15 35 Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision
16 of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and
17 clinimetric testing results. *Mov Disord* 2008;23(15):2129–70.
18
19
20 36 Dalrymple-Alford JC, MacAskill MR, Nakas CT, et al. The MoCA: well-suited screen for
21 cognitive impairment in Parkinson disease. *Neurology* 2010;75(19):1717–25.
22
23
24 37 Wang YP, Xu GL, Yang SQ, Liu XM, Deng XY. Value of Montreal Cognitive Assessment
25 in identifying patients with mild vascular cognitive impairment after first stroke. *Chinese*
26 *Journal of Neuromedicine* 2010;9(5):503–07.
27
28
29 38 Vitorio R, Stuart S, Gobbi LTB, et al. Reduced gait variability and enhanced brain activity
30 in older adults with auditory cues: a functional near-infrared spectroscopy study.
31 *Neurorehabil Neural Repair* 2018;32(11):976–87.
32
33
34 39 Yang N, Waddington G, Adams R, et al. Translation, cultural adaptation, and test-retest
35 reliability of Chinese versions of the Edinburgh Handedness Inventory and Waterloo
36 Footedness Questionnaire. *Laterality* 2018;23(3):255–73.
37
38
39 40 Wang S-M, Chan S-T, Wong Y-L, et al. Rhythmic auditory stimulation incorporated in
40 training improved movements in individuals with psychotic-like experiences. *Eur Arch*
41 *Psychiatry Clin Neurosci* 2022.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 41 Alan H.S. Chan. Upper limb length n.d. Available at:
4
5 <http://personal.cityu.edu.hk/meachan/Online%20Anthropometry/Chapter2/Ch2-24.htm>
6
7 Accessed August 21, 2022.
8
9
- 10 42 Mathiowetz V, Volland G, Kashman N, et al. Adult norms for the Box and Block Test of
11
12 manual dexterity. *Am J Occup Ther* 1985;39(6):386–91.
13
- 14 43 Desrosiers J, Bravo G, Hébert R, et al. Validation of the Box and Block Test as a measure of
15
16 dexterity of elderly people: reliability, validity, and norms studies. *Arch Phys Med Rehabil*
17
18 1994;75(7):751–55.
19
- 20 44 Jebsen RH, Taylor N, Trieschmann RB, et al. An objective and standardized test of hand
21
22 function. *Arch Phys Med Rehabil* 1969;50(6):311–19.
23
- 24 45 Dong VA, Fong KNK, Chen Y-F, et al. 'Remind-to-move' treatment versus constraint-
25
26 induced movement therapy for children with hemiplegic cerebral palsy: a randomized
27
28 controlled trial. *Dev Med Child Neurol* 2017;59(2):160–67.
29
- 30 46 Mak MKY, Lau ETL, Tam VWK, et al. Use of Jebsen Taylor Hand Function Test in
31
32 evaluating the hand dexterity in people with Parkinson's disease. *J Hand Ther*
33
34 2015;28(4):389-94; quiz 395.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Figure captions**
4

5 **Figure 1.** (A) The setup of the upper-limb training task. (B) The patient picks up one bead
6 from one target bowl and is going to move the bead to the main bowl.
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1

530x940mm (216 x 216 DPI)

Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin J, Dickersin K, Hróbjartsson A, Schulz KF, Parulekar WR, Krleža-Jerić K, Laupacis A, Moher D. SPIRIT 2013 Explanation and Elaboration: Guidance for protocols of clinical trials. *BMJ*. 2013;346:e7586

	Reporting Item	Page Number
Administrative information		
Title	#1 Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	#2a Trial identifier and registry name. If not yet registered,	2

1		name of intended registry	
2			
3			
4	Trial registration:	#2b All items from the World Health Organization Trial	2
5			
6	data set	Registration Data Set	
7			
8			
9	Protocol version	#3 Date and version identifier	n/a
10			
11			
12	Funding	#4 Sources and types of financial, material, and other	16
13			
14		support	
15			
16			
17	Roles and	#5a Names, affiliations, and roles of protocol contributors	16
18			
19	responsibilities:		
20			
21	contributorship		
22			
23			
24			
25	Roles and	#5b Name and contact information for the trial sponsor	1
26			
27	responsibilities:		
28			
29	sponsor contact		
30			
31	information		
32			
33			
34			
35	Roles and	#5c Role of study sponsor and funders, if any, in study	16
36			
37	responsibilities:	design; collection, management, analysis, and	
38			
39	sponsor and funder	interpretation of data; writing of the report; and the	
40			
41		decision to submit the report for publication, including	
42			
43		whether they will have ultimate authority over any of	
44			
45		these activities	
46			
47			
48			
49	Roles and	#5d Composition, roles, and responsibilities of the	16
50			
51	responsibilities:	coordinating centre, steering committee, endpoint	
52			
53	committees	adjudication committee, data management team, and	
54			
55		other individuals or groups overseeing the trial, if	
56			
57			
58			
59			
60			

1 applicable (see Item 21a for data monitoring
2
3 committee)

4
5
6 **Introduction**

7
8
9 Background and [#6a](#) Description of research question and justification for 5-7
10
11 rationale undertaking the trial, including summary of relevant
12
13 studies (published and unpublished) examining
14
15 benefits and harms for each intervention
16

17
18
19 Background and [#6b](#) Explanation for choice of comparators 5-7
20
21 rationale: choice of
22
23 comparators
24

25
26 Objectives [#7](#) Specific objectives or hypotheses 7
27

28
29 Trial design [#8](#) Description of trial design including type of trial (eg, 8
30
31 parallel group, crossover, factorial, single group),
32
33 allocation ratio, and framework (eg, superiority,
34
35 equivalence, non-inferiority, exploratory)
36
37

38
39 **Methods:**

40
41 **Participants,**
42
43 **interventions, and**
44
45 **outcomes**
46
47

48
49 Study setting [#9](#) Description of study settings (eg, community clinic, 8
50
51 academic hospital) and list of countries where data
52
53 will be collected. Reference to where list of study sites
54
55 can be obtained
56
57

1	Eligibility criteria	#10	Inclusion and exclusion criteria for participants. If	8
2				
3			applicable, eligibility criteria for study centres and	
4			individuals who will perform the interventions (eg,	
5			surgeons, psychotherapists)	
6				
7				
8				
9				
10				
11	Interventions:	#11a	Interventions for each group with sufficient detail to	9-13
12				
13	description		allow replication, including how and when they will be	
14			administered	
15				
16				
17				
18				
19	Interventions:	#11b	Criteria for discontinuing or modifying allocated	9-13
20				
21	modifications		interventions for a given trial participant (eg, drug	
22			dose change in response to harms, participant	
23			request, or improving / worsening disease)	
24				
25				
26				
27				
28				
29	Interventions:	#11c	Strategies to improve adherence to intervention	11
30				
31	adherence		protocols, and any procedures for monitoring	
32			adherence (eg, drug tablet return; laboratory tests)	
33				
34				
35				
36	Interventions:	#11d	Relevant concomitant care and interventions that are	11
37				
38	concomitant care		permitted or prohibited during the trial	
39				
40				
41				
42	Outcomes	#12	Primary, secondary, and other outcomes, including	13-14
43				
44			the specific measurement variable (eg, systolic blood	
45			pressure), analysis metric (eg, change from baseline,	
46			final value, time to event), method of aggregation (eg,	
47			median, proportion), and time point for each outcome.	
48				
49				
50				
51				
52				
53			Explanation of the clinical relevance of chosen	
54				
55			efficacy and harm outcomes is strongly recommended	
56				
57				
58				
59				
60				

1	Participant timeline	#13	Time schedule of enrolment, interventions (including	10-11
2			any run-ins and washouts), assessments, and visits	
3			for participants. A schematic diagram is highly	
4			recommended (see Figure)	
5				
6				
7				
8				
9				
10				
11	Sample size	#14	Estimated number of participants needed to achieve	9
12			study objectives and how it was determined, including	
13			clinical and statistical assumptions supporting any	
14			sample size calculations	
15				
16				
17				
18				
19				
20				
21	Recruitment	#15	Strategies for achieving adequate participant	8
22			enrolment to reach target sample size	
23				
24				
25				
26	Methods:			
27				
28	Assignment of			
29	interventions (for			
30	controlled trials)			
31				
32				
33				
34				
35				
36	Allocation: sequence	#16a	Method of generating the allocation sequence (eg,	8
37	generation		computer-generated random numbers), and list of any	
38			factors for stratification. To reduce predictability of a	
39			random sequence, details of any planned restriction	
40			(eg, blocking) should be provided in a separate	
41			document that is unavailable to those who enrol	
42			participants or assign interventions	
43				
44				
45				
46				
47				
48				
49				
50				
51				
52				
53	Allocation	#16b	Mechanism of implementing the allocation sequence	8
54	concealment		(eg, central telephone; sequentially numbered,	
55			opaque, sealed envelopes), describing any steps to	
56				
57				
58				
59				
60				

1		conceal the sequence until interventions are assigned	
2			
3			
4	Allocation:	#16c Who will generate the allocation sequence, who will	8
5			
6	implementation	enrol participants, and who will assign participants to	
7			
8		interventions	
9			
10			
11	Blinding (masking)	#17a Who will be blinded after assignment to interventions	8
12			
13		(eg, trial participants, care providers, outcome	
14			
15		assessors, data analysts), and how	
16			
17			
18			
19	Blinding (masking):	#17b If blinded, circumstances under which unblinding is	n/a
20			
21	emergency	permissible, and procedure for revealing a	
22			
23	unblinding	participant's allocated intervention during the trial	
24			
25			
26	Methods: Data		
27			
28	collection,		
29			
30	management, and		
31			
32	analysis		
33			
34			
35			
36	Data collection plan	#18a Plans for assessment and collection of outcome,	13-14
37			
38		baseline, and other trial data, including any related	
39			
40		processes to promote data quality (eg, duplicate	
41			
42		measurements, training of assessors) and a	
43			
44		description of study instruments (eg, questionnaires,	
45			
46		laboratory tests) along with their reliability and validity,	
47			
48		if known. Reference to where data collection forms	
49			
50		can be found, if not in the protocol	
51			
52			
53			
54			
55	Data collection plan:	#18b Plans to promote participant retention and complete	11
56			
57	retention	follow-up, including list of any outcome data to be	
58			
59			
60			

1		collected for participants who discontinue or deviate	
2		from intervention protocols	
3			
4			
5			
6	Data management	#19 Plans for data entry, coding, security, and storage,	14-15
7		including any related processes to promote data	
8		quality (eg, double data entry; range checks for data	
9		values). Reference to where details of data	
10		management procedures can be found, if not in the	
11		protocol	
12			
13			
14			
15			
16			
17			
18			
19			
20	Statistics: outcomes	#20a Statistical methods for analysing primary and	15
21		secondary outcomes. Reference to where other	
22		details of the statistical analysis plan can be found, if	
23		not in the protocol	
24			
25			
26			
27			
28			
29			
30	Statistics: additional	#20b Methods for any additional analyses (eg, subgroup	15
31	analyses	and adjusted analyses)	
32			
33			
34			
35	Statistics: analysis	#20c Definition of analysis population relating to protocol	15
36	population and	non-adherence (eg, as randomised analysis), and any	
37	missing data	statistical methods to handle missing data (eg,	
38		multiple imputation)	
39			
40			
41			
42			
43			
44			
45	Methods: Monitoring		
46			
47			
48	Data monitoring:	#21a Composition of data monitoring committee (DMC);	14-15
49	formal committee	summary of its role and reporting structure; statement	
50		of whether it is independent from the sponsor and	
51		competing interests; and reference to where further	
52		details about its charter can be found, if not in the	
53			
54			
55			
56			
57			
58			
59			
60			

1		protocol. Alternatively, an explanation of why a DMC	
2			
3		is not needed	
4			
5			
6	Data monitoring:	#21b Description of any interim analyses and stopping	14-15
7			
8	interim analysis	guidelines, including who will have access to these	
9			
10		interim results and make the final decision to	
11			
12		terminate the trial	
13			
14			
15			
16	Harms	#22 Plans for collecting, assessing, reporting, and	14-15
17			
18		managing solicited and spontaneously reported	
19			
20		adverse events and other unintended effects of trial	
21			
22		interventions or trial conduct	
23			
24			
25			
26	Auditing	#23 Frequency and procedures for auditing trial conduct, if	n/a
27			
28		any, and whether the process will be independent	
29			
30		from investigators and the sponsor	
31			
32			
33	Ethics and		
34			
35	dissemination		
36			
37			
38			
39	Research ethics	#24 Plans for seeking research ethics committee /	16
40			
41	approval	institutional review board (REC / IRB) approval	
42			
43			
44	Protocol	#25 Plans for communicating important protocol	15
45			
46	amendments	modifications (eg, changes to eligibility criteria,	
47			
48		outcomes, analyses) to relevant parties (eg,	
49			
50		investigators, REC / IRBs, trial participants, trial	
51			
52		registries, journals, regulators)	
53			
54			
55			
56	Consent or assent	#26a Who will obtain informed consent or assent from	16
57			
58			
59			
60			

1		potential trial participants or authorised surrogates,	
2			
3		and how (see Item 32)	
4			
5			
6	Consent or assent:	#26b Additional consent provisions for collection and use of	n/a
7			
8	ancillary studies	participant data and biological specimens in ancillary	
9			
10		studies, if applicable	
11			
12			
13	Confidentiality	#27 How personal information about potential and enrolled	16
14			
15		participants will be collected, shared, and maintained	
16			
17		in order to protect confidentiality before, during, and	
18			
19		after the trial	
20			
21			
22			
23	Declaration of	#28 Financial and other competing interests for principal	16
24			
25	interests	investigators for the overall trial and each study site	
26			
27			
28			
29	Data access	#29 Statement of who will have access to the final trial	15
30			
31		dataset, and disclosure of contractual agreements that	
32			
33		limit such access for investigators	
34			
35			
36	Ancillary and post	#30 Provisions, if any, for ancillary and post-trial care, and	n/a
37			
38	trial care	for compensation to those who suffer harm from trial	
39			
40		participation	
41			
42			
43			
44	Dissemination	#31a Plans for investigators and sponsor to communicate	8
45			
46	policy: trial results	trial results to participants, healthcare professionals,	
47			
48		the public, and other relevant groups (eg, via	
49			
50		publication, reporting in results databases, or other	
51			
52		data sharing arrangements), including any publication	
53			
54		restrictions	
55			
56			
57			
58			
59			
60			

1	Dissemination	#31b	Authorship eligibility guidelines and any intended use	1
2				
3	policy: authorship		of professional writers	
4				
5				
6	Dissemination	#31c	Plans, if any, for granting public access to the full	n/a
7				
8	policy: reproducible		protocol, participant-level dataset, and statistical code	
9				
10	research			
11				
12				
13				
14	Appendices			
15				
16				
17	Informed consent	#32	Model consent form and other related documentation	Supplemental
18				
19	materials		given to participants and authorised surrogates	Material
20				
21				
22				
23	Biological specimens	#33	Plans for collection, laboratory evaluation, and storage	n/a
24				
25			of biological specimens for genetic or molecular	
26				
27			analysis in the current trial and for future use in	
28				
29			ancillary studies, if applicable	
30				
31				

32 The SPIRIT Explanation and Elaboration paper is distributed under the terms of the Creative
 33 Commons Attribution License CC-BY-NC. This checklist was completed on 13. June 2023 using
 34 <https://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with
 35 [Penelope.ai](#)